Edd Fleming, M.D.

Edd serves as a board member to Sionna and is Executive Vice President of Commercialization at Enavate Sciences where he invests in and builds therapeutic companies. In 2022, Edd retired as Senior Partner and leader in the life science practice at McKinsey & Company where he worked extensively with both large and small biopharmaceutical companies on their strategic and operational priorities. He was the global leader of McKinsey’s R&D practice where he was responsible for its client service and knowledge development on R&D topics. Edd earned his B.A. in Chemistry from Harvard University, his M.D. from Vanderbilt University, and completed internal medicine training at Johns Hopkins Hospital and subspecialty training in pulmonary and critical care medicine at the University of California, San Francisco. Edd serves on the Boards of CRISPR Therapeutics, Komodo Health, Upstream Bio, Orso Bio, Sudo Biosciences, Egnite Health and the Board of Visitors for Vanderbilt’s School of Basic Sciences.